Australia's most trusted
source of pharma news
Saturday, 27 April 2024
Posted 21 June 2022 PM
An antitrust investigation opened by the European Commission into Vifor Pharma could set CSL's acquisition of the company back even further.
CSL previously revealed it didn't expect to reach its June deadline, due to "regulatory approval processes" taking longer than expected.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.